{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:12:07Z","timestamp":1792012327784,"version":"4.4.0"},"reference-count":47,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Bcr-Abl tyrosine kinase inhibitors (TKIs) have been a remarkable success for the treatment of Ph+ chronic myeloid leukemia (CML). However, a significant proportion of patients treated with TKIs develop resistance because of leukemia stem cells (LSCs) and T315I mutant Bcr-Abl. Here we describe the unknown activity of the natural product berbamine that efficiently eradicates LSCs and T315I mutant Bcr-Abl clones. Unexpectedly, we identify CaMKII \u03b3 as a specific and critical target of berbamine for its antileukemia activity. Berbamine specifically binds to the ATP-binding pocket of CaMKII \u03b3, inhibits its phosphorylation and triggers apoptosis of leukemia cells. More importantly, CaMKII \u03b3 is highly activated in LSCs but not in normal hematopoietic stem cells and coactivates LSC-related \u03b2-catenin and Stat3 signaling networks. The identification of CaMKII \u03b3 as a specific target of berbamine and as a critical molecular switch regulating multiple LSC-related signaling pathways can explain the unique antileukemia activity of berbamine. These findings also suggest that berbamine may be the first ATP-competitive inhibitor of CaMKII \u03b3, and potentially, can serve as a new type of molecular targeted agent through inhibition of the CaMKII \u03b3 activity for treatment of leukemia.<\/jats:p>","DOI":"10.1182\/blood-2012-06-434894","type":"journal-article","created":{"date-parts":[[2012,10,18]],"date-time":"2012-10-18T09:49:24Z","timestamp":1350553764000},"page":"4829-4839","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":102,"title":["CaMKII \u03b3, a critical regulator of CML stem\/progenitor cells, is a target of the natural product berbamine"],"prefix":"10.1182","volume":"120","author":[{"given":"Ying","family":"Gu","sequence":"first","affiliation":[{"name":"Department of Hematology, Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, and"},{"name":"Cancer Institute, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China;"},{"name":"Division of Gene Regulation and Drug Discovery and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhipeng","family":"Meng","sequence":"additional","affiliation":[{"name":"Division of Gene Regulation and Drug Discovery and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichao","family":"Gan","sequence":"additional","affiliation":[{"name":"Department of Hematology, Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiyu","family":"Lou","sequence":"additional","affiliation":[{"name":"Division of Gene Regulation and Drug Discovery and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongzhi","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxian","family":"Gan","sequence":"additional","affiliation":[{"name":"Zhejiang Academy of Medical Sciences, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Hematology, Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinfen","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genbo","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liansheng","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongming","family":"Fang","sequence":"additional","affiliation":[{"name":"Cancer Institute, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Wang","sequence":"additional","affiliation":[{"name":"Cancer Institute, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Zheng","sequence":"additional","affiliation":[{"name":"Cancer Institute, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendong","family":"Huang","sequence":"additional","affiliation":[{"name":"Division of Gene Regulation and Drug Discovery and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongzhen","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, and"},{"name":"Cancer Institute, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2019111811401415400_B1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nrm1280","article-title":"Regulation of the c-Abl and Bcr-Abl tyrosine kinases.","volume":"5","author":"Hantschel","year":"2004","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"5405","key":"2019111811401415400_B2","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining.","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"issue":"10","key":"2019111811401415400_B3","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343.h8003343_3343_3356","article-title":"The molecular biology of chronic myeloid leukemia.","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"issue":"9","key":"2019111811401415400_B4","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.4161\/cc.8.9.8209","article-title":"The CML stem cell: evolution of the progenitor.","volume":"8","author":"Stuart","year":"2009","journal-title":"Cell Cycle"},{"issue":"6","key":"2019111811401415400_B5","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1111\/j.1582-4934.2007.00108.x","article-title":"Stem cell and kinase activity-independent pathway in resistance of leukaemia to BCR-ABL kinase inhibitors.","volume":"11","author":"Li","year":"2007","journal-title":"J Cell Mol Med"},{"issue":"4","key":"2019111811401415400_B6","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/sj.leu.2405086","article-title":"Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors.","volume":"22","author":"Konig","year":"2008","journal-title":"Leukemia"},{"issue":"23","key":"2019111811401415400_B7","doi-asserted-by":"crossref","first-page":"9809","DOI":"10.1158\/0008-5472.CAN-08-1008","article-title":"Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression.","volume":"68","author":"Mahon","year":"2008","journal-title":"Cancer Res"},{"issue":"1","key":"2019111811401415400_B8","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/leu.2008.262","article-title":"beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia.","volume":"23","author":"Hu","year":"2009","journal-title":"Leukemia"},{"issue":"8","key":"2019111811401415400_B9","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/leu.2009.52","article-title":"Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice.","volume":"23","author":"Chen","year":"2009","journal-title":"Leukemia"},{"issue":"5975","key":"2019111811401415400_B10","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1126\/science.1183424","article-title":"Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.","volume":"328","author":"Zhang","year":"2010","journal-title":"Science"},{"issue":"3","key":"2019111811401415400_B11","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/nchembio.522","article-title":"XPB, a subunit of TFIIH, is a target of the natural product triptolide.","volume":"7","author":"Titov","year":"2011","journal-title":"Nat Chem Biol"},{"issue":"6","key":"2019111811401415400_B12","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0024-3205(02)02200-2","article-title":"A comparative study on the anti-inflammatory, anti-nociceptive and anti-pyretic effects of isoquinoline alkaloids from the roots of Turkish Berberis species.","volume":"72","author":"Kupeli","year":"2002","journal-title":"Life Sci"},{"issue":"1-2","key":"2019111811401415400_B13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0378-4347(01)00277-8","article-title":"Analytical approaches for traditional chinese medicines exhibiting anti-neoplastic activity.","volume":"764","author":"Tsai","year":"2001","journal-title":"J Chromatogr B Biomed Sci Appl"},{"issue":"2","key":"2019111811401415400_B14","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.4049\/jimmunol.181.2.1491","article-title":"Novel immunomodulatory properties of berbamine through selective down-regulation of STAT4 and action of IFN-gamma in experimental autoimmune encephalomyelitis.","volume":"181","author":"Ren","year":"2008","journal-title":"J Immunol"},{"issue":"8","key":"2019111811401415400_B15","doi-asserted-by":"crossref","first-page":"PL53","DOI":"10.1016\/0024-3205(92)90373-W","article-title":"Comparative effects of tetrandrine and berbamine on production of the inflammatory cytokines interleukin-1 and tumor necrosis factor.","volume":"50","author":"Seow","year":"1992","journal-title":"Life Sci"},{"issue":"5","key":"2019111811401415400_B16","first-page":"759","article-title":"The effect of calmodulin antagonist berbaminederivative-EBB on hepatoma in vitro and in vivo.","volume":"115","author":"Liu","year":"2002","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"2019111811401415400_B17","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.leukres.2005.05.023","article-title":"Berbamine: a novel inhibitor of bcr\/abl fusion gene with potent anti-leukemia activity.","volume":"30","author":"Xu","year":"2006","journal-title":"Leuk Res"},{"issue":"8","key":"2019111811401415400_B18","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1016\/j.ejmech.2009.02.018","article-title":"Berbamine derivatives: a novel class of compounds for anti-leukemia activity.","volume":"44","author":"Xie","year":"2009","journal-title":"Eur J Med Chem"},{"issue":"7","key":"2019111811401415400_B19","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1631\/jzus.B1000230","article-title":"Berbamine inhibits proliferation and induces apoptosis of KU812 cells by increasing Smad3 activity.","volume":"12","author":"Liang","year":"2011","journal-title":"J Zhejiang Univ Sci B"},{"issue":"7","key":"2019111811401415400_B20","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1002\/ar.20924","article-title":"The anti-proliferation effect of berbamine on k562 resistant cells by inhibiting NF-kappaB pathway.","volume":"292","author":"Wei","year":"2009","journal-title":"Anat Rec (Hoboken)"},{"issue":"9","key":"2019111811401415400_B21","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1097\/00029330-200705010-00012","article-title":"Berbamine selectively induces apoptosis of human acute promyelocytic leukemia cells via survivin-mediated pathway.","volume":"120","author":"Zhao","year":"2007","journal-title":"Chin Med J (Engl)"},{"issue":"3","key":"2019111811401415400_B22","first-page":"709","article-title":"4-Chlorobenzoyl berbamine induces apoptosis and G2\/M cell cycle arrest through the PI3K\/Akt and NF-kappaB signal pathway in lymphoma cells.","volume":"23","author":"Du","year":"2010","journal-title":"Oncol Rep"},{"issue":"12","key":"2019111811401415400_B23","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1038\/aps.2009.167","article-title":"Berbamine, a novel nuclear factor kappaB inhibitor, inhibits growth and induces apoptosis in human myeloma cells.","volume":"30","author":"Liang","year":"2009","journal-title":"Acta Pharmacol Sin"},{"issue":"7","key":"2019111811401415400_B24","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1002\/jps.22082","article-title":"A novel calmodulin antagonist O-(4-ethoxyl-butyl)-berbamine overcomes multidrug resistance in drug-resistant MCF-7\/ADR breast carcinoma cells.","volume":"99","author":"Liu","year":"2010","journal-title":"J Pharm Sci"},{"issue":"4","key":"2019111811401415400_B25","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s10616-009-9240-x","article-title":"Suppression of human lung cancer cell growth and migration by berbamine.","volume":"62","author":"Duan","year":"2010","journal-title":"Cytotechnology"},{"issue":"3","key":"2019111811401415400_B26","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/10286020802675076","article-title":"Berbamine induces Fas-mediated apoptosis in human hepatocellular carcinoma HepG2 cells and inhibits its tumor growth in nude mice.","volume":"11","author":"Wang","year":"2009","journal-title":"J Asian Nat Prod Res"},{"key":"2019111811401415400_B27","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1476-4598-8-81","article-title":"Suppression of growth, migration and invasion of highly-metastatic human breast cancer cells by berbamine and its molecular mechanisms of action.","volume":"8","author":"Wang","year":"2009","journal-title":"Mol Cancer"},{"issue":"1","key":"2019111811401415400_B28","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/0006-291X(86)91113-7","article-title":"A derivative of bisbenzylisoquinoline alkaloid is a new and potential calmodulin antagonist.","volume":"140","author":"Xu","year":"1986","journal-title":"Biochem Biophys Res Commun"},{"issue":"11","key":"2019111811401415400_B29","first-page":"1143","article-title":"Effect of E6, a novel calmodulin inhibitor, on activity of P-glycoprotein in purified primary cultured rat brain microvessel endothelial cells.","volume":"24","author":"Zhu","year":"2003","journal-title":"Acta Pharmacol Sin"},{"issue":"3","key":"2019111811401415400_B30","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0922-4106(95)90075-6","article-title":"Effect of berbamine on cytosolic phospholipase A2 activation in rabbit platelets.","volume":"291","author":"Akiba","year":"1995","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"2019111811401415400_B31","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0898-6568(89)90008-9","article-title":"Benzylisoquinoline compounds inhibit the ability of calmodulin to activate cyclic nucleotide phosphodiesterase.","volume":"1","author":"Hu","year":"1989","journal-title":"Cell Signal"},{"issue":"7","key":"2019111811401415400_B32","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1055\/s-2002-32896","article-title":"Inhibition of telomerase activity and bcl-2 expression in berbamine-induced apoptosis in HL-60 cells.","volume":"68","author":"Ji","year":"2002","journal-title":"Planta Med"},{"issue":"8","key":"2019111811401415400_B33","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/0006-2952(92)90470-4","article-title":"Interaction of berbamine compound E6 and calmodulin-dependent myosin light chain kinase.","volume":"44","author":"Hu","year":"1992","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"2019111811401415400_B34","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1471-4159.1991.tb02595.x","article-title":"Staurosporine: an effective inhibitor for Ca2+\/calmodulin-dependent protein kinase II.","volume":"56","author":"Yanagihara","year":"1991","journal-title":"J Neurochem"},{"issue":"1","key":"2019111811401415400_B35","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.","volume":"121","author":"Corbin","year":"2011","journal-title":"J Clin Invest"},{"issue":"6","key":"2019111811401415400_B36","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","article-title":"Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival.","volume":"119","author":"Hamilton","year":"2012","journal-title":"Blood"},{"issue":"8","key":"2019111811401415400_B37","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1182\/blood.V98.8.2301","article-title":"Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells.","volume":"98","author":"Guzman","year":"2001","journal-title":"Blood"},{"issue":"38","key":"2019111811401415400_B38","doi-asserted-by":"crossref","first-page":"36008","DOI":"10.1074\/jbc.M106125200","article-title":"Calmodulin-dependent kinase II mediates T cell receptor\/CD3- and phorbol ester-induced activation of IkappaB kinase.","volume":"276","author":"Hughes","year":"2001","journal-title":"J Biol Chem"},{"issue":"10","key":"2019111811401415400_B39","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1158\/0008-5472.CAN-07-2509","article-title":"Activated Ca2+\/calmodulin-dependent protein kinase IIgamma is a critical regulator of myeloid leukemia cell proliferation.","volume":"68","author":"Si","year":"2008","journal-title":"Cancer Res"},{"issue":"19","key":"2019111811401415400_B40","doi-asserted-by":"crossref","first-page":"7587","DOI":"10.1158\/0008-5472.CAN-09-1180","article-title":"Targeted disruption of stat3 reveals a major role for follicular stem cells in skin tumor initiation.","volume":"69","author":"Kim","year":"2009","journal-title":"Cancer Res"},{"issue":"10","key":"2019111811401415400_B41","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1002\/stem.185","article-title":"STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells.","volume":"27","author":"Sherry","year":"2009","journal-title":"Stem Cells"},{"issue":"3","key":"2019111811401415400_B42","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1104\/pp.15.3.563","article-title":"Isolation of the Alkaloids, Berberine and Berbamine, from Mahonia Swaseyi.","volume":"15","author":"Greathouse","year":"1940","journal-title":"Plant Physiol"},{"issue":"5","key":"2019111811401415400_B43","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1172\/JCI30779","article-title":"CaMKII regulates retinoic acid receptor transcriptional activity and the differentiation of myeloid leukemia cells.","volume":"117","author":"Si","year":"2007","journal-title":"J Clin Invest"},{"issue":"3","key":"2019111811401415400_B44","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/jcp.21076","article-title":"Calcium\/calmodulin-dependent kinase activity is required for efficient induction of osteoclast differentiation and bone resorption by receptor activator of nuclear factor kappa B ligand (RANKL).","volume":"212","author":"Ang","year":"2007","journal-title":"J Cell Physiol"},{"issue":"6","key":"2019111811401415400_B45","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1161\/01.RES.0000182630.29093.0d","article-title":"Targeting of a novel Ca+2\/calmodulin-dependent protein kinase II is essential for extracellular signal-regulated kinase-mediated signaling in differentiated smooth muscle cells.","volume":"97","author":"Marganski","year":"2005","journal-title":"Circ Res"},{"issue":"6","key":"2019111811401415400_B46","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.freeradbiomed.2009.06.022","article-title":"CaMKII knockdown attenuates H2O2-induced phosphorylation of ERK1\/2, PKB\/Akt, and IGF-1R in vascular smooth muscle cells.","volume":"47","author":"Bouallegue","year":"2009","journal-title":"Free Radic Biol Med"},{"issue":"3","key":"2019111811401415400_B47","first-page":"201","article-title":"Determination of berbamine in rat plasma by reversed phase high performance liquid chromatography.","volume":"29","author":"Li","year":"1995","journal-title":"J Harbin Med Univ"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/24\/4829\/1360782\/zh805012004829.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/24\/4829\/1360782\/zh805012004829.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T11:49:56Z","timestamp":1574077796000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/120\/24\/4829\/30989\/CaMKII-%CE%B3-a-critical-regulator-of-CML"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,6]]},"references-count":47,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2012,12,6]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-06-434894","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,6]]}}}